<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668432</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20150864H</org_study_id>
    <nct_id>NCT02668432</nct_id>
  </id_info>
  <brief_title>Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock</brief_title>
  <official_title>Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose/Objectives: Severe sepsis and septic shock are a common cause of new onset atrial&#xD;
      fibrillation (NOAF) in the intensive care unit. Development of NOAF in this setting can&#xD;
      prolong length of stay and increase mortality. Amiodarone is the most commonly used agent&#xD;
      used in this setting to control rate and rhythm. However, limited data exist detailing&#xD;
      appropriate dosing in this setting. The primary objective of this study is to evaluate two&#xD;
      amiodarone dosing strategies, a full loading dose versus a partial loading dose, in patients&#xD;
      with new-onset atrial fibrillation (AF) due to severe sepsis or septic shock to assess the&#xD;
      mean heart rate every 6 hours after initiation of amiodarone infusion to day 7 or death.&#xD;
&#xD;
      Research Design/Plan: Consecutive patients admitted to the medical or cardiac intensive care&#xD;
      unit at University Hospital with NOAF in the setting of severe sepsis or septic shock will be&#xD;
      screened for study inclusion. Data will be collected and stored using Microsoft Excel or&#xD;
      Access and analyzed with JMP 12.0 and SPSS.&#xD;
&#xD;
      Methods: Patients aged 18 years or older who develop new-onset atrial fibrillation in the&#xD;
      setting of severe sepsis or septic shock and in whom the medical team deems appropriate to&#xD;
      initiate amiodarone therapy in will be considered for study inclusion. Patients will receive&#xD;
      intravenous (IV) and oral (PO) amiodarone, as per the standard of care. Patients will be&#xD;
      randomized to a certain quantitative loading dose strategy; either a full loading dose (≥ 5g&#xD;
      IV or ≥10g PO +/- 20%) or a partial loading dose (&lt;4g IV or &lt; 8g PO).&#xD;
&#xD;
      Clinical Relevance: With intensive care unit length of stay (ICU LOS) and mortality being&#xD;
      twice as high in NOAF with sepsis as compared to septic patients without NOAF, the&#xD;
      investigators ultimately aim to identify a management strategy that may minimize this&#xD;
      morbidity and mortality while also minimizing exposure to a drug that may cause serious&#xD;
      adverse effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Step-by-Step Methods:&#xD;
&#xD;
      Population: The study will be conducted at University Hospital, the 716-bed county hospital&#xD;
      for Bexar County and serves a varied population, including patients from medically&#xD;
      underserved areas. The patient population will come from the medical intensive care unit and&#xD;
      the cardiac intensive care unit, a 20 and 26-bed unit, respectively, at University Hospital&#xD;
      that is the clinical practice and teaching site for one study investigator.&#xD;
&#xD;
      Screening: Consecutive patients admitted to the medical or cardiac intensive care unit at&#xD;
      University Hospital with new onset atrial fibrillation in the setting of severe sepsis or&#xD;
      septic shock will be screened for study inclusion. Participants will be 18 years or older.&#xD;
      Patients who develop new-onset atrial fibrillation in the setting of severe sepsis or septic&#xD;
      shock will be considered for study inclusion. Exclusion criteria apply to those younger than&#xD;
      18 years of age, those with a history of atrial flutter, baseline QTc (a measurement made on&#xD;
      a electrocardiogram which measures the start of the Q wave to the end of the T wave) &gt; 500&#xD;
      msec, atrial fibrillation during the index admission or in their past medical history, second&#xD;
      or third degree atrioventricular (AV) block, those recovering from cardiac surgery done&#xD;
      during the same hospital admission, those who have received amiodarone or other Vaughan&#xD;
      Williams class I or III antiarrhythmic drugs in the last 6 months, untreated/poorly&#xD;
      controlled hypothyroidism, hyperthyroidism, acute or chronic hepatic failure, other&#xD;
      requirements of antiarrhythmic drug therapy, recent cardiac surgery in the preceding 30 days,&#xD;
      and those who are pregnant.&#xD;
&#xD;
      Intervention: Patients aged 18 years or older who develop new-onset atrial fibrillation in&#xD;
      the setting of severe sepsis or septic shock and in whom the medical team deems appropriate&#xD;
      to initiate amiodarone therapy in will be considered for study inclusion. All patients will&#xD;
      receive a 150 mg IV bolus dose of amiodarone, followed immediately by a continuous infusion&#xD;
      of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently.&#xD;
      Conversion from IV to PO amiodarone will occur based on patient hemodynamic stability and&#xD;
      physician/pharmacist discretion. Patients will be randomized to receive amiodarone at a full&#xD;
      loading dose (≥ 5g IV or ≥10g PO +/- 20%) or a partial loading dose (&lt;4g IV or &lt; 8g PO). The&#xD;
      assigned total loading dose will include all IV and PO amiodarone administered within 7 days&#xD;
      from initiation of amiodarone. All doses will be compared in total PO amount (accounting for&#xD;
      50% bioavailability of PO versus IV amiodarone). The primary attending or fellow physician&#xD;
      may over-ride randomization if the patient's amiodarone dose if the patient's severity of&#xD;
      illness warrants a duration that differs from that assigned during randomization. In the full&#xD;
      loading dose group, discontinuation of amiodarone will be at the discretion of the&#xD;
      physician/pharmacists, after the pre-determined randomization loading dose has been provided.&#xD;
&#xD;
      Management Components: Facilities to be used throughout the project include the University&#xD;
      Hospital and The University of Texas Health Science Center at San Antonio. Equipment use for&#xD;
      direct patient care will be in keeping with standards-of-care, without any additional&#xD;
      equipment being required for the clinical research study.&#xD;
&#xD;
      Data Collection: Data collection will include age, race, gender, body mass index (BMI), data&#xD;
      for calculating an Acute Physiology and Chronic Health Evaluation (APACHE II) and Sequential&#xD;
      Organ Failure Assessment (SOFA) scores, suspected source of infection, identified pathogens,&#xD;
      pre-existing conditions that may predispose the patient to AF and the severity/classification&#xD;
      of such illness (coronary artery disease, heart failure, chronic kidney disease, chronic&#xD;
      obstructive pulmonary disease, diabetes mellitus); vital signs at the onset of AF (mean&#xD;
      arterial pressure, systolic blood pressure, heart rate), lactate, pH (scale of acidity), and&#xD;
      serum bicarbonate at the time of AF onset; fluid resuscitation volume for the 24 hours prior&#xD;
      to AF, vasopressor use (including drug, dose, duration) in the preceding 24 hours; other&#xD;
      medications used to stabilize hemodynamic status in AF (e.g. β-blockers, calcium channel&#xD;
      blockers, digoxin), other attempted methods of cardioversion attempted prior to amiodarone&#xD;
      use (e.g. direct current cardioversion, other antiarrhythmic drug therapy); amiodarone&#xD;
      loading dose, cumulative study amiodarone dose; the duration of time spent in AF before&#xD;
      conversion to normal sinus rhythm (NSR), the incidence of AF recurrence; and hemodynamic&#xD;
      variables to be assessed at various time points after the initiation of amiodarone (-6 hours,&#xD;
      at onset of AF, 2 hours, 6 hours, 12 hours, and every 6 hours thereafter until day 7 or&#xD;
      death) including mean arterial pressure, central venous pressure, systolic blood pressure,&#xD;
      heart rate, pH, serum bicarbonate, and serum lactate.&#xD;
&#xD;
      Monitoring for Efficacy and Safety:&#xD;
&#xD;
      Efficacy: Patients will be stratified based on response to therapy into one of three groups:&#xD;
      conversion to NSR, non-converting AF that is hemodynamically stable or non-converting AF that&#xD;
      is hemodynamically unstable. The primary efficacy outcome is the mean heart rate every 6&#xD;
      hours after initiation of the amiodarone infusion to day 7 or death. Secondary efficacy&#xD;
      endpoints will include the percentage of time spent hemodynamically unstable in the first 7&#xD;
      days following amiodarone initiation, ICU LOS, hospital LOS and 28-day mortality along with&#xD;
      comparisons of the individual portions of the hemodynamic endpoints [mean arterial pressure&#xD;
      (MAP), heart rate (HR), systolic blood pressure(SBP)], cumulative vasopressor doses of&#xD;
      norepinephrine and vasopressin, central venous pressure (CPR), conversion to NSR, maintenance&#xD;
      of NSR, proportion of time spent in NSR after the start of the infusion to day 7 or death,&#xD;
      pH, standard bicarbonate, serum lactate, and central venous oxygen saturation.&#xD;
&#xD;
      Safety: Safety outcomes include worsening of hypotension (largely related to the rate of&#xD;
      infusion and the polysorbate 80 diluent), bradycardia, acute elevations of liver function&#xD;
      tests ≥ 3 times the upper limit of normal, phlebitis, QTc prolongation, skin reactions,&#xD;
      neuropathy, and pulmonary toxicity. We will also collect premature study discontinuation due&#xD;
      to any adverse event. Because the experimental group of this study is a partial load of&#xD;
      amiodarone, rather than a full load, it is likely that the experimental group will experience&#xD;
      fewer amiodarone related adverse effects than those receiving the current practice. In the&#xD;
      setting of worsening hemodynamic stability during amiodarone infusion (i.e. SBP &lt;90 mmHg OR&#xD;
      MAP &lt; 70 mmHg, despite HR control of &lt; 120 bpm; need for fluid boluses ± vasopressors or&#xD;
      dobutamine), which the medical team believes to be caused by IV amiodarone therapy:&#xD;
&#xD;
        1. the amiodarone infusion rate should be decreased by 50%, with efforts to increase back&#xD;
           to the standard infusion rate after the patient is hemodynamically stable, or&#xD;
&#xD;
        2. switch from IV amiodarone to PO amiodarone therapy at a dose of 400 mg PO three times&#xD;
           daily (TID), or&#xD;
&#xD;
        3. emergent electro-cardioversion at the discretion of the medical team (as is the standard&#xD;
           of care)&#xD;
&#xD;
      Data Analysis Plan: Data will be collected and stored using Microsoft Excel or Access. After&#xD;
      data organization and cleaning, data will be imported into JMP 12.0 or SPSS. Data will be&#xD;
      analyzed using both descriptive and comparative statistics. The primary outcome will be&#xD;
      analyzed using repeated measures ANOVA. Nominal and ordinal variables will be compared using&#xD;
      Chi-square test or Fisher's Exact test, as appropriate. Continuous variables will be tested&#xD;
      for normality using the Shapiro-Wilk W goodness of fit test. Continuous variables with normal&#xD;
      distributions will be compared using the student's t-test, while non-parametric variables&#xD;
      will be compared using the Wilcoxon rank sum test. Statistical significance will be defined&#xD;
      as an alpha level less than 0.05.&#xD;
&#xD;
      All baseline demographics, including patient comorbidities, amount of fluid resuscitation,&#xD;
      previous vasoactive therapies, and use of other interventions such as direct current&#xD;
      cardioversion, will be entered into a multivariate regression model if the p value is less&#xD;
      than 0.20 on univariate comparison between treatment groups. The multivariate regression&#xD;
      model will be used to assess if baseline factors or previous treatment other than the&#xD;
      intervention affected the study outcomes.&#xD;
&#xD;
      Based on extrapolation from available literature assessing HR control at 24 hours, we&#xD;
      estimate that the full loading dose group will have a mean HR of 110 bpm over the course of 7&#xD;
      days, while the partial loading dose group will have a mean HR of 130 bpm over the course of&#xD;
      7 days. 7 day mean HR that is 20 bpm lower than the partial loading dose group. Therefore, we&#xD;
      estimate that 250 patients will be necessary in each group to have an 85% power to detect a&#xD;
      difference, assuming a 15% drop-out rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator left institution&#xD;
  </why_stopped>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">September 20, 2018</completion_date>
  <primary_completion_date type="Actual">September 20, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean HR Every 6 Hours Within the First 7 Days</measure>
    <time_frame>7 days</time_frame>
    <description>Evaluate two amiodarone dosing strategies, a full loading dose versus a partial loading dose, in patients with new-onset atrial fibrillation (AF) due to severe sepsis or septic shock to assess the effect on:&#xD;
• Mean heart rate every 6 hours within the first 7 days following initiation of amiodarone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent Hemodynamically Unstable After Initiation of Amiodarone Infusion to Day 7 or Death</measure>
    <time_frame>7 days</time_frame>
    <description>Hemodynamic instability: 1. SBP &lt;90 mmHg OR MAP &lt; 70 mmHg AND HR ≥ 120 bp for ≥ 2 hours OR 2. HR ≥ 120 for ≥ 2 hours OR 3. Fluid boluses ± vasopressors or dobutamine. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time of Conversion to Normal Sinus Rhythm</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage of time patients spent with conversion from atrial fibrillation to normal sinus rhythm. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Patients Spent in Atrial Fibrillation</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage of time in atrial fibrillation vs normal sinus rhythm or other during a 7 day period. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial Pressure (MAP)</measure>
    <time_frame>7 days</time_frame>
    <description>Mean arterial pressure (MAP) measured over 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure (SBP)</measure>
    <time_frame>7 days</time_frame>
    <description>Systolic blood pressure (SBP) measured over 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR)</measure>
    <time_frame>7 days</time_frame>
    <description>Heart rate (HR) measured over 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Time of Vasopressor Norepinephrine Use</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage time of Use of the vasopressor Norepinephrine in addition to the amiodarone. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Time of Vasopressor Vasopressin Use</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage time of use of the vasopressor Vasopressin in addition to amiodarone. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time of Vasopressor Phenylephrine Use</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage of time of use of the vasopressor Phenylephrine in addition to amiodarone. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time of Corticosteroid Use</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage of time of use of a corticosteroid for treatment in addition to amiodarone use. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time of Dobutamine Use</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage of time of use of Dobutamine in addition to amiodarone intervention. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time of Concomitant Rate Control Medication Use</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage of time of Additional medications used to control heart rate in addition to amiodarone. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant Rhythm Control Medication or Intervention Use</measure>
    <time_frame>7 days</time_frame>
    <description>Use of additional medications used with amiodarone to control heart rhythm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Survival to 28 days post initiation of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Length of Stay (ICU LOS)</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days spent in intensive care unit after admission.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>New Onset Atrial Fibrillation</condition>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Partial Load</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive &lt;4g IV or &lt; 8g PO. The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Full Load</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive (≥ 5g IV or ≥10g PO +/- 20%). The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO equivalents (accounting for 50% bioavailability of PO vs IV amiodarone). Randomization may be overridden by the attending or fellow physician if the patient's severity of illness warrants. Discontinuation of amiodarone in the full-load group will be at the discretion of the physician/pharmacists, after the pre-determined randomization loading dose has been provided.</description>
    <arm_group_label>Full Load</arm_group_label>
    <arm_group_label>Partial Load</arm_group_label>
    <other_name>Cordarone</other_name>
    <other_name>Pacerone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New onset atrial fibrillation&#xD;
&#xD;
          -  Severe sepsis or septic shock (defined by ≥2 systemic inflammatory response syndrome&#xD;
             criteria + infection)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  History of atrial flutter&#xD;
&#xD;
          -  History of atrial fibrillation&#xD;
&#xD;
          -  QTc &gt;500 msec at baseline&#xD;
&#xD;
          -  2nd or 3rd degree AV block&#xD;
&#xD;
          -  Currently receiving anti-arrhythmic therapy&#xD;
&#xD;
          -  Untreated thyroid dysfunction&#xD;
&#xD;
          -  Acute or chronic hepatic failure&#xD;
&#xD;
          -  Other indication for antiarrhythmic therapy&#xD;
&#xD;
          -  Recent cardiac surgery in last 30 days&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bethany A Kalich</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <results_first_submitted>November 19, 2018</results_first_submitted>
  <results_first_submitted_qc>March 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2019</results_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02668432/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Partial Load</title>
          <description>150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by continuous infusion 1 mg/min for 6 hours, with a reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients will receive &lt;4g IV or &lt; 8g PO. The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).&#xD;
Amiodarone: Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO amiodarone</description>
        </group>
        <group group_id="P2">
          <title>Full Load</title>
          <description>All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive (≥ 5g IV or ≥10g PO +/- 20%). The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).&#xD;
Amiodarone: Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Partial Load</title>
          <description>150 mg intravenous (IV) bolus dose of amiodarone, followed by continuous infusion of 1 mg/min for 6 hours, with recommended reduction to 0.5 mg/min. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive &lt;4g IV or &lt; 8g PO. The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).&#xD;
Amiodarone: Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO amiodarone</description>
        </group>
        <group group_id="B2">
          <title>Full Load</title>
          <description>All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive (≥ 5g IV or ≥10g PO +/- 20%). The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).&#xD;
Amiodarone: Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.21" spread="16.5"/>
                    <measurement group_id="B2" value="54.8" spread="10.27"/>
                    <measurement group_id="B3" value="62" spread="13.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean HR Every 6 Hours Within the First 7 Days</title>
        <description>Evaluate two amiodarone dosing strategies, a full loading dose versus a partial loading dose, in patients with new-onset atrial fibrillation (AF) due to severe sepsis or septic shock to assess the effect on:&#xD;
• Mean heart rate every 6 hours within the first 7 days following initiation of amiodarone</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Mean HR Every 6 Hours Within the First 7 Days</title>
          <description>Evaluate two amiodarone dosing strategies, a full loading dose versus a partial loading dose, in patients with new-onset atrial fibrillation (AF) due to severe sepsis or septic shock to assess the effect on:&#xD;
• Mean heart rate every 6 hours within the first 7 days following initiation of amiodarone</description>
          <units>Beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average heart rate measured every 6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" spread="16"/>
                    <measurement group_id="O2" value="122" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average heart rate measured at 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="8"/>
                    <measurement group_id="O2" value="94.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent Hemodynamically Unstable After Initiation of Amiodarone Infusion to Day 7 or Death</title>
        <description>Hemodynamic instability: 1. SBP &lt;90 mmHg OR MAP &lt; 70 mmHg AND HR ≥ 120 bp for ≥ 2 hours OR 2. HR ≥ 120 for ≥ 2 hours OR 3. Fluid boluses ± vasopressors or dobutamine. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent Hemodynamically Unstable After Initiation of Amiodarone Infusion to Day 7 or Death</title>
          <description>Hemodynamic instability: 1. SBP &lt;90 mmHg OR MAP &lt; 70 mmHg AND HR ≥ 120 bp for ≥ 2 hours OR 2. HR ≥ 120 for ≥ 2 hours OR 3. Fluid boluses ± vasopressors or dobutamine. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
          <units>percentage of time</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time of Conversion to Normal Sinus Rhythm</title>
        <description>Percentage of time patients spent with conversion from atrial fibrillation to normal sinus rhythm. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time of Conversion to Normal Sinus Rhythm</title>
          <description>Percentage of time patients spent with conversion from atrial fibrillation to normal sinus rhythm. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
          <units>percentage of time</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Patients Spent in Atrial Fibrillation</title>
        <description>Percentage of time in atrial fibrillation vs normal sinus rhythm or other during a 7 day period. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Patients Spent in Atrial Fibrillation</title>
          <description>Percentage of time in atrial fibrillation vs normal sinus rhythm or other during a 7 day period. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
          <units>percentage of time</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial Pressure (MAP)</title>
        <description>Mean arterial pressure (MAP) measured over 7 days</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial Pressure (MAP)</title>
          <description>Mean arterial pressure (MAP) measured over 7 days</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="60" upper_limit="73"/>
                    <measurement group_id="O2" value="75" lower_limit="17" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure (SBP)</title>
        <description>Systolic blood pressure (SBP) measured over 7 days</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure (SBP)</title>
          <description>Systolic blood pressure (SBP) measured over 7 days</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108" lower_limit="89" upper_limit="114"/>
                    <measurement group_id="O2" value="124" lower_limit="99" upper_limit="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate (HR)</title>
        <description>Heart rate (HR) measured over 7 days</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate (HR)</title>
          <description>Heart rate (HR) measured over 7 days</description>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="66" upper_limit="80"/>
                    <measurement group_id="O2" value="85" lower_limit="78" upper_limit="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Time of Vasopressor Norepinephrine Use</title>
        <description>Percentage time of Use of the vasopressor Norepinephrine in addition to the amiodarone. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Time of Vasopressor Norepinephrine Use</title>
          <description>Percentage time of Use of the vasopressor Norepinephrine in addition to the amiodarone. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
          <units>percentage of time</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Time of Vasopressor Vasopressin Use</title>
        <description>Percentage time of use of the vasopressor Vasopressin in addition to amiodarone. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Time of Vasopressor Vasopressin Use</title>
          <description>Percentage time of use of the vasopressor Vasopressin in addition to amiodarone. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
          <units>percentage of time</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time of Vasopressor Phenylephrine Use</title>
        <description>Percentage of time of use of the vasopressor Phenylephrine in addition to amiodarone. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time of Vasopressor Phenylephrine Use</title>
          <description>Percentage of time of use of the vasopressor Phenylephrine in addition to amiodarone. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
          <units>percentage of time</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time of Corticosteroid Use</title>
        <description>Percentage of time of use of a corticosteroid for treatment in addition to amiodarone use. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time of Corticosteroid Use</title>
          <description>Percentage of time of use of a corticosteroid for treatment in addition to amiodarone use. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
          <units>percentage of time</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time of Dobutamine Use</title>
        <description>Percentage of time of use of Dobutamine in addition to amiodarone intervention. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time of Dobutamine Use</title>
          <description>Percentage of time of use of Dobutamine in addition to amiodarone intervention. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
          <units>percentage of time</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time of Concomitant Rate Control Medication Use</title>
        <description>Percentage of time of Additional medications used to control heart rate in addition to amiodarone. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time of Concomitant Rate Control Medication Use</title>
          <description>Percentage of time of Additional medications used to control heart rate in addition to amiodarone. The reported data represents a cumulative percentage of time for the entire group of participants.</description>
          <units>percentage of time</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concomitant Rhythm Control Medication or Intervention Use</title>
        <description>Use of additional medications used with amiodarone to control heart rhythm.</description>
        <time_frame>7 days</time_frame>
        <population>Outcome measure data were not collected or analyzed for this outcome, study terminated early due to lack of funding and due to Investigator leaving institution</population>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Concomitant Rhythm Control Medication or Intervention Use</title>
          <description>Use of additional medications used with amiodarone to control heart rhythm.</description>
          <population>Outcome measure data were not collected or analyzed for this outcome, study terminated early due to lack of funding and due to Investigator leaving institution</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>28-day Mortality</title>
        <description>Survival to 28 days post initiation of treatment.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>28-day Mortality</title>
          <description>Survival to 28 days post initiation of treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Care Unit Length of Stay (ICU LOS)</title>
        <description>Number of days spent in intensive care unit after admission.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Partial Load</title>
            <description>&lt; 10g oral loading dose of amiodarone</description>
          </group>
          <group group_id="O2">
            <title>Full Load</title>
            <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit Length of Stay (ICU LOS)</title>
          <description>Number of days spent in intensive care unit after admission.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="3.5" upper_limit="14.75"/>
                    <measurement group_id="O2" value="6" lower_limit="5" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Partial Load</title>
          <description>&lt; 10g oral loading dose of amiodarone</description>
        </group>
        <group group_id="E2">
          <title>Full Load</title>
          <description>10 g (+/- 20%) oral loading dose of amiodarone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bethany Kalich, PharmD</name_or_title>
      <organization>University of Texas Health San Antonio</organization>
      <phone>210-883-1177</phone>
      <email>kalich@uiwtx.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

